NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in
Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma
with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of
Europe (CIRSE) annual meeting. The abstract, Survival and Response of Patients with Metastatic Ocular Melanoma after
Chemosaturation Percutaneous Hepatic Perfusion, will be presented by M. Zeile, and A. Stang, et al of the Asklepios Barmbek
Clinic in Hamburg, Germany.
The CIRSE 2018 annual meeting will be held in Lisbon, Portugal September 22-25, 2018.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and
metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic
Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure
and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular
Melanoma (OM) and has initiated a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved
by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available
since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major
medical centers to treat a wide range of cancers of the liver.
Forward Looking Statements
Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made
by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to: successful completion of the Company’s Rights Offering and related
transactions and the amount of gross proceeds, if any; the timing and results of the Company’s clinical trials including without
limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM and ICC
clinical trials, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from participating sites
and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical
conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests for
reimbursement of the CHEMOSAT procedure, the impact, if any of ZE reimbursement on potential CHEMOSAT product use and sales in
Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe
including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT
system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in
the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the current or future
Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in
the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s ability to successfully
enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same,
uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company’s
ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities.
These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should
not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no
obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are
made.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
